Revolution Medicines (RVMD) Other Non-Current Liabilities (2019 - 2026)

Revolution Medicines' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 817.2% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 817.2% YoY), while the FY2025 annual figure was $18.5 million, up 2668.06% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $6.9 million, down from $18.5 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $18.5 million in Q4 2025, with the low at $219000.0 in Q2 2022.
• The 5-year median for Other Non-Current Liabilities is $1.5 million (2023), against an average of $3.0 million.
• Peak annual rise in Other Non-Current Liabilities reached 2668.06% in 2025, while the deepest fall reached 76.24% in 2025.
• Revolution Medicines' Other Non-Current Liabilities stood at $301000.0 in 2022, then jumped by 384.39% to $1.5 million in 2023, then tumbled by 54.05% to $670000.0 in 2024, then surged by 2668.06% to $18.5 million in 2025, then sank by 62.91% to $6.9 million in 2026.
• Business Quant data shows RVMD's Other Non-Current Liabilities at $6.9 million in Q1 2026, $18.5 million in Q4 2025, and $2.5 million in Q3 2025.